StephanMollMD
Oncology • Chapel Hill, NCProfessor of Medicine, University of North Carolina at Chapel Hill School of Medicine
Dr. Moll is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
101 Manning Dr
Chapel Hill, NC 27599Phone+1 919-966-3311Fax+1 919-843-4896
Education & Training
Duke University HospitalFellowship, Hematology and Medical Oncology, 1993 - 1996- Duke University HospitalResidency, Internal Medicine, 1989 - 1992
Albert Ludwigs University Faculty of MedicineClass of 1986
Certifications & Licensure
NC State Medical License 1993 - 2025- American Board of Internal Medicine Hematology
Clinical Trials
- Daily Vitamin K in Patients on Warfarin With Unstable INRs Start of enrollment: 2005 Oct 01
- Once Weekly Subcutaneous Ports for the Administration of Anticoagulants Start of enrollment: 2008 Aug 01
- Acute Venous Thrombosis: Thrombus Removal With Adjunctive Catheter-Directed Thrombolysis Start of enrollment: 2009 Nov 01
- Join now to see all
Publications & Presentations
PubMed
- 6 citationsEmicizumab reduces re-hospitalization for bleeding in acquired haemophilia A.Sheh-Li Chen, Patrick Ellsworth, Raj S. Kasthuri, Stephan Moll, Alice D. Ma
Haemophilia. 2021-05-29 - 72 citationsDelivery of Optimized Anticoagulant Therapy: Consensus Statement from the Anticoagulation ForumDavid A. Garcia, Daniel M. Witt, Elaine M. Hylek, Ann K. Wittkowsky, Edith A. Nutescu
The Annals of Pharmacotherapy. 2008-07-01 - 6 citationsLeukocytosis due to markedly elevated granulocyte-colony stimulating factor levels in a patient with endometrial cancer: Case report and literature reviewLeslie H. Clark, Stephan Moll, Damon E. Houghton, Siohban O'Connor, John T. Soper
Gynecologic Oncology Reports. 2017-01-22
Abstracts/Posters
- Incidence and Time Course of Neutropenia in Patients Treated with Rituximab-Based Therapy for Non-Malignant Immune-Mediated Hematologic DiseasesStephan Moll, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Adherence to Infectious Disease Screening and Immunization Guidelines When Treating Non-Malignant Immune-Mediated Hematologic DisordersStephan Moll, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
Lectures
- High-Performance Hematology: Elite Athletes and Weekend Warriors60th American Society of Hematology Annual Meeting - 12/3/2018
- Recombinant Porcine Factor VIII Use in Bleed Treatment in Non-Severe Hemophilia a Inhibitor Patients: Dosing Strategies and Efficacy2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Press Mentions
Does Omicron Pose as Much of a Blood Clot Threat?January 24th, 2022- The Eye of a SurvivorAugust 2nd, 2021
- Here's How NASA Treats Astronauts Who Get Sick in SpaceApril 7th, 2021
- Join now to see all
Other Languages
- German
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
